Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7911
Reference
MSAN(2023)12
Name
GLP-1 receptor agonists used in the management of type 2 diabetes
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
SUPPLIES
DRUG SHORTAGES
Description
There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes Mellitus (T2DM). Supply is not expected to return to normal until at least mid-2024. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications. Please refer to the Specialist Pharmacists Service (SPS) Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative treatment options (see paragraph 24 for further information).Other alternative somatropin products remain available but may require a change in formulation and/or dosing regimen.
Contact Name
Contact Email
Contact Address
Pharmacy & Medicines Division 1st Floor East Rear St Andrew’s House EDINBURGH EH1 3DG
Created
2023-07-12 00:00:00
Click to go back to homepage